OSTEOPORE LIMITED — Capital/Financing Update 2022

Jun 13, 2022

ASX RELEASE | OSTEOPORE LIMITED

==> picture [145 x 60] intentionally omitted <==

OSTEOPORE EXPANDS INTO AFRICA WITH INITIAL SALES TO SOUTH AFRICA

Highlights:

• Osteopore expands its footprint to Africa with the first shipment of its cranial regenerative implants to South Africa.

• The initial sales represent an endorsement of Osteopore’s continued strategy to penetrate new markets and drive uptake amongst surgeons, and follows recent entry into Colombia and Spain.

• Osteopore will harness this opportunity to expand collaborations with local surgeons and gain new regulatory access in additional Africa territories.

• Osteopore’s regenerative implants are now sold in every contingent.

14 June 2022: Osteopore Limited (ASX: OSX) (“Osteopore” or the “Company”), an Australian and Singapore based global leader in the manufacture of innovative regenerative implants that empower natural tissue regeneration, is pleased to announce it has successfully expanded into the African market with its first shipment of cranial (skull) regenerative implants to South Africa.

Osteopore’s cranial implants can be manufactured at scale and dissolve over time to leave only natural healthy bone. They have largely outperformed traditional implant methods in terms of design, post-surgery complications and associated long-term health care costs.

The initial orders were received from Osteopore’s South Africa based distribution partner, Chronos Medical, who will promote the technology to their extensive network of hospitals and surgeons across the country. Osteopore’s implants have also successfully been cleared for marketing and sales by the South African Health Products Regulatory Authority.

While the initial South Africa sales are not material in terms of revenue, it does represent an endorsement of Osteopore’s continued strategy to penetrate new markets and drive adoption amongst surgeons. Over the past two months, Osteopore has achieved first sales in Colombia and Spain, and also signed a distribution agreement to sell orbit reconstruction products within Australia and New Zealand.

Osteopore has regulatory access and operation in more than 20 countries and autonomous regions, including the US, Europe, Asia, and Australia. The Company aims to gain additional regulatory access in new markets and continue to execute on its vision to become the standard-of-care for bone and tissue regeneration globally.

Osteopore Limited (ACN 630 538 957)│ASX:OSX│16 Ord Street, West Perth│+618 9482 0500│www.osteopore.com

==> picture [145 x 60] intentionally omitted <==

Osteopore Executive Chairman, Mark Leong said, “Achieving first sales into South Africa is a fantastic milestone for the company, and is evidence of the team’s execution ability to open new markets. This follows our recent entry into Colombia and Spain. We plan to harness this opportunity and work towards increasing adoption in South Africa and the African continent, as well as continue to building an economic moat around the Company’s novel technology. We are proud that our regenerative implants are now sold in every continent. ”

Chronos Medical Director, Tristan Baijnath, and Co-Director, Dean Twigg, said, “We are thrilled to be bringing Osteopore to our shores and cannot wait to see the difference this astounding product makes in the lives of our surgeons and patients."

This announcement has been approved for release by the Board of Osteopore.

For more information, please contact:

Mark Leong

Executive Chairman Osteopore Limited +65 9011 7009 Mark_Leong@osteopore.com

About Osteopore Limited

Osteopore Limited is an Australian and Singapore based medical technology company commercialising a range of bespoke products specifically engineered to facilitate bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material. Osteopore's patent-protected scaffolds are made from proprietary polymer formulations that naturally dissolve over time to leave only natural, healthy bone tissue, significantly reducing post-surgery complications commonly associated with permanent bone implants.

About Chronos Medical

Chronos Medical is a distributor located in South Africa's most populous province of Gauteng. Although a relatively young company, the business has experienced great support over the first two years of operations, and have established themselves as an effective brand in the medical industry with loyal clientele and experienced staff.

Forward-Looking Statements

Statements contained in this release, particularly those regarding possible or assumed future performance, revenue, costs, dividends, production levels or rates, prices, or potential growth of Osteopore Limited, are, or may be, forward-looking statements. Such statements relate to future events and expectations and, as such, involve known and unknown risks and uncertainties. Actual results may differ materially from those expressed or implied by these forward-looking statements depending on various factors.

Osteopore Limited (ACN 630 538 957)│ASX:OSX│16 Ord Street, West Perth│+618 9482 0500│www.osteopore.com